

## PUBLIC SUMMARY DOCUMENT

**Product:** Dansac NovaLife TRE 2 Soft Convex Wafer

**Applicant:** Dansac

**Date of SPAP Meeting:** 12 October 2021

### 1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Dansac, sought listing of the Dansac NovaLife TRE 2 Soft Convex Wafer in subgroup 4(c) of the Stoma Appliance Scheme (the Scheme) Schedule. The product including six variants was proposed for listing at the unit price of \$5.839, with a maximum monthly quantity of 20 units.

### 2. Comparator

The applicant nominated Dansac NovaLife TRE Convex Baseplate (SAS Code 3941K) as the comparator. This product is currently listed in subgroup 4(c) of the SAS Schedule at the unit price of \$5.839 with a maximum monthly quantity of 20 units. The Stoma Product Assessment Panel (SPAP) accepted this product as an appropriate comparator.

### 3. Background

This was the SPAP's first consideration of this product.

### 4. Clinical Place for the Product

The proposed product will provide an alternative for users requiring a two-piece mechanical coupling convex.

### 5. SPAP Comment

#### Clinical Analysis

The Panel noted that the proposed product is an extension to the TRE range listed on the Scheme Schedule. The Panel also noted the TRE barrier is a hydrocolloid barrier material with high absorption and cohesive properties which assists to protect the skin and provides a seal around the stoma.

The Panel agreed the proposed product provides an alternative to what is currently listed in subgroup 4(c) of the SAS Schedule.

#### Economic Analysis

Not undertaken.

#### Financial Analysis

It is therefore, unlikely that there would be any budgetary impact for the Scheme as a consequence of listing this product.

### 6. SPAP Recommendation

The SPAP recommended that the Dansac NovaLife TRE 2 Soft Convex Wafer, including six variants, be listed in subgroup 4(c) of the Scheme Schedule at the unit price of \$5.839, with a maximum monthly quantity of 20 units on a cost minimisation basis compared to products currently listed in subgroup 4(c) of the Scheme Schedule.

### 7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

### 8. Applicant's Comment

Dansac agrees with the SPAP recommendation.